Sanofi pays Regeneron $1B to expand antibody alliance

· Health · France · United States

Sanofi will pay $1 billion upfront to broaden its long-running antibody collaboration with Regeneron, aiming to develop long-acting drugs against the same targets as their blockbuster anti-inflammatory Dupixent. The deal comes as Dupixent's patent cliff approaches.

Why it matters：It shows how large pharma is trying to replace revenue from aging blockbusters by extending proven partnerships into next-generation biologics.

Key points

  • The upfront payment is $1 billion.
  • The partners will pursue long-acting antibodies against Dupixent's targets.
  • Sanofi is turning back to the partnership that built the megablockbuster.

Sources (original reporting)

More stories from this day